Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace; Obesity drugs’ next tests, and rising threats: 3 chronic disease stories to watch

Taking stock of the drug industry, from the lab to the medicine chest

December 21, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace A new study analyzes tactics used to manipulate the patent system — patent thickets and terminal disclaimers. By Ed Silverman Obesity drugs' next tests, and rising threats: 3 chronic disease stories to watch While drugs like Wegovy and Zepbound made obesity a top topic in 2023, there are other chronic illnesses that are rising. By Isabella Cueto and Elaine Chen STAT+ | Drugs are still mostly tested in white men. Will the FDA change that next year? Congress gave the FDA more power to get companies to racially diversify clinical trials, and we'll soon see how the agency uses it. By John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser